SG11201806696WA - Anti-citrullinated hla polypeptide antibodies and uses thereof - Google Patents

Anti-citrullinated hla polypeptide antibodies and uses thereof

Info

Publication number
SG11201806696WA
SG11201806696WA SG11201806696WA SG11201806696WA SG11201806696WA SG 11201806696W A SG11201806696W A SG 11201806696WA SG 11201806696W A SG11201806696W A SG 11201806696WA SG 11201806696W A SG11201806696W A SG 11201806696WA SG 11201806696W A SG11201806696W A SG 11201806696WA
Authority
SG
Singapore
Prior art keywords
international
rrcitaa
qrcitaa
michigan
citrullinated
Prior art date
Application number
SG11201806696WA
Other languages
English (en)
Inventor
James Leslie Mobley
Original Assignee
Cayman Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayman Chemical Co Inc filed Critical Cayman Chemical Co Inc
Publication of SG11201806696WA publication Critical patent/SG11201806696WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11201806696WA 2016-02-10 2017-02-10 Anti-citrullinated hla polypeptide antibodies and uses thereof SG11201806696WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662293621P 2016-02-10 2016-02-10
PCT/US2017/017373 WO2017139577A1 (en) 2016-02-10 2017-02-10 Anti-citrullinated hla polypeptide antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201806696WA true SG11201806696WA (en) 2018-09-27

Family

ID=59563430

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806696WA SG11201806696WA (en) 2016-02-10 2017-02-10 Anti-citrullinated hla polypeptide antibodies and uses thereof

Country Status (14)

Country Link
US (1) US20190048086A1 (ko)
EP (1) EP3413905A4 (ko)
JP (1) JP2019508415A (ko)
KR (1) KR20180105710A (ko)
CN (1) CN108883151A (ko)
AU (1) AU2017217814A1 (ko)
BR (1) BR112018016383A2 (ko)
CA (1) CA3014079A1 (ko)
EA (1) EA201891800A1 (ko)
IL (1) IL260994A (ko)
MX (1) MX2018009696A (ko)
PH (1) PH12018501674A1 (ko)
SG (1) SG11201806696WA (ko)
WO (1) WO2017139577A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3713966A1 (en) 2017-11-22 2020-09-30 Vacara AB Antibodies to citrullinated proteins
WO2020168168A1 (en) * 2019-02-15 2020-08-20 Inova Diagnostics, Inc. Compositions and methods for diagnosing and assessing rheumatoid arthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562943B1 (en) * 1999-04-21 2003-05-13 Zycos, Inc. Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
EP1603937A2 (en) * 2003-03-07 2005-12-14 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
CN105251004A (zh) * 2006-12-26 2016-01-20 分子免疫中心 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
US10132806B2 (en) * 2011-10-21 2018-11-20 Augurex Life Sciences Corp. Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013109279A2 (en) * 2012-01-19 2013-07-25 Therapeutic Proteins Inc. Stabilization of the anti-cd20 antibody rituximab

Also Published As

Publication number Publication date
EA201891800A1 (ru) 2019-01-31
AU2017217814A1 (en) 2018-08-23
BR112018016383A2 (pt) 2018-12-18
WO2017139577A1 (en) 2017-08-17
JP2019508415A (ja) 2019-03-28
CN108883151A (zh) 2018-11-23
EP3413905A4 (en) 2019-07-24
MX2018009696A (es) 2018-11-09
KR20180105710A (ko) 2018-09-28
CA3014079A1 (en) 2017-08-17
PH12018501674A1 (en) 2019-06-10
IL260994A (en) 2018-10-31
EP3413905A1 (en) 2018-12-19
US20190048086A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809751XA (en) Egfr inhibitor compounds
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201807677YA (en) Antibodies to cd40 with enhanced agonist activity
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof